Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that ...

The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our development pipeline. We are grateful to the patients, researchers, trial investigators, and ...

The National Institutes of Health has awarded $2.9 million to Arkansas Children's Research Institute to examine how a critical therapy for patients with cystic fibrosis might become even more ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Contineum Therapeutics (CTNM) stock gains as Baird launches coverage with an Outperform rating, highlighting the potential of ...

The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

The RespiriNTM project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU) under grant agreement No 853932. This Joined Undertaking receives support from the European ...

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to contribute to advancing healthcare through pioneering ...